SOPH

At a glance

SOPHiA GENETICS SA (SOPH) is listed on NASDAQ and classified in Health Information Services, part of the Healthcare sector. It is headquartered in Rolle, Switzerland and has 415 employees. The company is worth $572.91M. Revenue was $77.27M in fiscal 2025, up 18.6% from the year before. It reported a net loss of $79M. The share price is 25.1% below its 52-week high of $8.98. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Akre Capital (Akre Capital Management), at $21.46M. Over the last 30 days, company insiders sold $795.52K of its stock on the open market and bought none. $126.7K of those sales were scheduled in advance under 10b5-1 plans.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$572.91M

P/E

—

Forward P/E

—

P/B

6.9x

Dividend yield

0.00%

Payout

—

EPS

-$1.16

ROE

-101.22%

Profit margin

-93.86%

Revenue growth

+27.20%

Beta

0.95

52-week high

$8.98

52-week low

$3.75

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• AC
  Akre CapitalHeld

  Akre Capital Management · Q2 2026
  $21.46M

  3.72M shares · 0.4% of portfolio
• IE
  Israel EnglanderHeld

  Millennium Management · Q2 2026
  $798.62K

  138.41K shares · 0.0% of portfolio
• RT
  Renaissance TechnologiesHeld

  Renaissance Technologies · Q2 2026
  $653.74K

  113.3K shares · 0.0% of portfolio

Indicators, year by year

The last 4 closed years, each at that year’s closing price and reported numbers.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company